Mediation effect of herpes zoster derived by statin use on cardiovascular disease risk
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Sung-Han | - |
dc.contributor.author | Yun, Sung-Cheol | - |
dc.contributor.author | Khang, Young-Ho | - |
dc.contributor.author | Kim, Min-Chul | - |
dc.contributor.author | Kwon, Sun Uck | - |
dc.contributor.author | Park, Gyung-Min | - |
dc.contributor.author | Cho, Young-Rak | - |
dc.contributor.author | Lee, Kwang Min | - |
dc.contributor.author | Kim, Moo Hyun | - |
dc.date.accessioned | 2023-03-08T13:52:22Z | - |
dc.date.available | 2023-03-08T13:52:22Z | - |
dc.date.issued | 2020-09 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.issn | 2005-6648 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/63273 | - |
dc.description.abstract | Background/Aims: Although statins are widely used to reduce the risk of cardiovascular disease (CVD) including stroke and myocardial infarction (MI), it is reported that statin use increases the incidence of herpes zoster (HZ) that is associated with increased risk of CVD. So, we evaluated the mediation effect of HZ caused by statin use on CVD. Methods: We analyzed a prospective cohort from the National Health Insurance Service-database of South Korea. All individuals received a medical check-up and were followed-up from 2002 to 2013. Results: A total of 275,382 individuals > 40 years old were followed up for 11 years from 2003. Of these, 11,415 people (4%) were classified as statin users and 263,967 (96%) as non-statin users. Those who used statins had significantly lower risks of cardiovascular events, stroke, and MI compared with non-statin users; the adjusted hazard ratios in the multivariate analysis were 0.90 (95% confidence interval [CI], 0.82 to 0.98), 0.88 (95% CI, 0.80 to 0.98), and 0.91(95% CI, 0.79 to 1.07), respectively. When we calculated the mediating effect of cardiovascular events by statin use through HZ, 11.6% of the total beneficial effect of cardiovascular events by statin use was mitigated through the occurrence of HZ caused by statin use. This mediating effect was higher in the younger age group (< 60 years). Conclusions: This study showed that statin use reduced CVD by 10%, but the protective effect of statin use against CVD was mitigated by approximately 10% through the development of HZ caused by statin use. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN ASSOC INTERNAL MEDICINE | - |
dc.title | Mediation effect of herpes zoster derived by statin use on cardiovascular disease risk | - |
dc.type | Article | - |
dc.identifier.doi | 10.3904/kjim.2019.020 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, v.35, no.5, pp 1220 - 1228 | - |
dc.identifier.kciid | ART002616269 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000564331000021 | - |
dc.identifier.scopusid | 2-s2.0-85090920540 | - |
dc.citation.endPage | 1228 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1220 | - |
dc.citation.title | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.volume | 35 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Herpes zoster | - |
dc.subject.keywordAuthor | Stroke | - |
dc.subject.keywordAuthor | Myocardial infarction | - |
dc.subject.keywordPlus | STROKE | - |
dc.subject.keywordPlus | ADULTS | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.